Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2045

Annual patent cliff calendar for 2045 — US pharmaceutical patents by expiration date.

Patents
1,566

Quick answer

1,566 indexed pharmaceutical patents have expiration dates in 2045. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 12337199

    Stable antibody formulation

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12337017

    Microbiota transfer therapy for Pitt Hopkins Syndrome

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12336990

    Treatment of prostate cancer

    Takeda Pharmaceutical Company Limited · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12336835

    Neuromodulation to target glucose transporter and/or incretin pathways

    GE Precision Healthcare LLC · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12336974

    Methods and compositions for preventing and treating auditory dysfunctions

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12338274

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12338437

    OPA1 antisense oligomers for treatment of conditions and diseases

    STOKE THERAPEUTICS, INC. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12338459

    DNA-chimeric antigen receptor T cells for immunotherapy

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12338269

    IL-2 superagonists in combination with anti-PD-1 antibodies

    Medicenna Therapeutics Inc. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12338219

    Antimalarial agents

    MSD R&D (China) Co. Ltd. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12337033

    Encapsulated glycolipid antigens for treatment of neoplastic diseases

    EnGeneIC Molecular Delivery Pty Ltd · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12336976

    Glutaminase inhibitor therapy

    The Board of Regents of the University of Texas System · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12338450

    Gene therapy constructs for treating Wilson disease

    Ultragenyx Pharmaceutical Inc. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12338438

    Conjugated oligonucleotide compounds, methods of making and uses thereof

    E-Therapeutics PLC · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12338439

    Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. WO 2025137347

    FORMULATIONS DE RISANKIZUMAB À HAUTE CONCENTRATION

    ABBVIE INC [US] · Granted Thu Jun 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jun 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. WO 2025132620

    PRÉPARATIONS DE CAPSULE MOLLE STABLES À REMPLISSAGE SOLIDE POUR PRINCIPES ACTIFS SENSIBLES À L'HUMIDITÉ

    BAYER CONSUMER CARE AG [CH] · Granted Thu Jun 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jun 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. WO 2025133253

    EXCIPIENTS DE CONJUGAISON PROTÉINIQUES POUR ADMINISTRATION INTRANUCLÉAIRE

    ABLYNX NV [BE] · Granted Thu Jun 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jun 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. WO 2025133166

    VÉHICULES À BASE DE PROTÉINES POUR CONJUGAISON D'AMINE SPÉCIFIQUE À UN SITE

    ABLYNX NV [BE] · Granted Thu Jun 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jun 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. WO 2025133252

    DOMAINES VARIABLES UNIQUES D'IMMUNOGLOBULINE CIBLANT CEACAM5

    ABLYNX NV [BE] · Granted Thu Jun 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jun 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12343357

    Compositions and methods for modulating MECP2 expression

    Ionis Pharmaceuticals, Inc. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12344578

    Salt forms of bempedoic acid and methods for using the same

    Esperion Therapeutics, Inc. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12344665

    Treatment of fibrodysplasia ossificans progressiva by administration of an anti-activin a antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12344691

    Resin composition for stereolithography

    KURARAY NORITAKE DENTAL INC. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12344842

    Compositions and methods for treating and preventing macular degeneration

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12343337

    Compounds for increasing neural plasticity

    The Regents of the University of California · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12345709

    CLAUDIN18 antibodies and methods of treating cancer

    The Regents of the University of California · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12344677

    Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12344656

    Genetically engineered T cells having improved persistence in culture

    CRISPR THERAPEUTICS AG · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12343448

    Use of stem cells produced by stem cell generator in treatment of hematopoietic damage

    East China University of Science and Technology · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12343381

    Dosage regimen for pegylated interferon

    PHARMAESSENTIA CORPORATION · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12343380

    Expansion of TILs utilizing AKT pathways inhibitors

    Iovance Biotherapeutics, Inc. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12343350

    Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)

    Windtree Therapeutics, Inc. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12343342

    Methods for treating soft tissue sarcoma

    Lixte Biotechnology, Inc. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12343324

    Dihydromyricetin hot melt extrusion formulations and methods for forming them

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12343424

    Photochemically stable, non-leaching, bridged polysilsesquioxane based sunscreens

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12343388

    Clostridioides difficile TcdB variants, vaccines and methods of use

    The Board of Regents of the University of Oklahoma · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12343394

    CD38 modulating antibody agents

    BLACK BELT THERAPEUTICS LIMITED · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12344676

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    PRECISION BIOLOGICS, INC. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12344654

    Mage A4 T cell receptors

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12343398

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12344585

    Crystalline salts of a plasma kallikrein inhibitor

    BioCryst Pharmaceuticals, Inc. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12343432

    Encapsulated probiotic

    UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12343321

    Method for ameliorating or avoiding the adverse effects of exogenous gonadotropins on reproductive performance

    China Agricultural University · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12343348

    Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome

    ESSENTIALIS, INC. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12344655

    Gene-edited natural killer cells

    CRISPR THERAPEUTICS AG · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12343397

    Drug-resistant immune cells and methods of use thereof

    Regents of the University of Minnesota · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12344596

    Solid forms of (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and salts thereof

    LEXICON PHARMACEUTICALS, INC. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2045?

1,566 published patents in our USPTO index have expiration dates falling in calendar year 2045.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.